Select publications | Research To Practice

Submitted by web@researchtop... on Wed, 03/18/2020 - 12:33

Select Publications

Richard S Finn, MD

Cainap C et al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial. J Clin Oncol 2015;33(2):172-9. Abstract

Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity 2013;39(1):1-10. Abstract

Cheng AL et al. IMBRAVE150: Efficacy and safety results from a PH III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). ESMO Asia 2019;Abstract LBA3.

Cheng AL et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial. J Clin Oncol 2013;31(32):4067-75. Abstract

Facciabene A et al. Tumor hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011;475(7355):226-30. Abstract

Gabrilovich DI et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2(10):1096-103. Abstract

Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9(3):162-74. Abstract

Goel S et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011;91(3):1071-121. Abstract

Hegde PS et al. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol 2018;52(Pt 2):117-24. Abstract

Hodi FS et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014;2(7):632-42. Abstract

Johnson PJ et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study. J Clin Oncol 2013;31(28):3517-24. Abstract

Kudo M et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomized phase 3 non-inferiority trial. Lancet 2018;391(10126):1163-73. Abstract

Matsui J et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008;122(3):664-71. Abstract

Matsui J et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008;14(17):5459-65. Abstract

Motz GT et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014;20(6):607-15. Abstract

Oyama T et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998;160(3):1224-32. Abstract

Roland CL et al. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One 2009;4(11):e7669. Abstract

Tohyama O et al. Antitumor activity of lenvatinib (e7080): An angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014:638747. Abstract

Voron T et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med 2015;212(2):139-48. Abstract

Wallin JJ et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun 2016;7:12624. Abstract

Yamamoto Y et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 2014;6:18. Abstract

Yau T et al. CheckMate 459: A randomized, multi-center phase 3 study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). ESMO 2019;Abstract LBA38_PR.

Zhu AX et al. SEARCH: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2015;33(6):559-66. Abstract

Andrew X Zhu, MD, PhD

Abou Alfa GK et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018;379(1):54-63. Abstract

Bruix J et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389(10064):56-66. Abstract

Finn RS et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol 2018;69(2):353-58. Abstract

Kline CL, El-Deiry WS. Personalizing colon cancer therapeutics: Targeting old and new mechanisms of action. Pharmaceuticals (Basel) 2013;6(8):988-1038. Abstract

Trojan J, Waidmann O. Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma. J Hepatocell Carcinoma 2016;3:31-36. Abstract

Zhu AX et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): A randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20(2):282-96. Abstract

Zhu AX et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomized, double-blind, multicenter, phase 3 trial. Lancet Oncol 2015;16(7):859-70. Abstract

Anthony El-Khoueiry, MD

Crocenzi TS et al. Nivolumab (nivo) in sorafenib (sor)-naÏve and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study. ASCO 2017;Abstract 4013.

El-Khoueiry AB et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389(10088):2492-502. Abstract

Finn RS et al. Pembrolizumab (pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240. ESMO Gastrointestinal Cancers Symposium 2019;Abstract O-027.

Kudo M et al. Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status. Gastrointestinal Cancers Symposium 2019;Abstract 327.

Zhu AX et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomized, open-label phase 2 trial. Lancet Oncol 2018;19(7):940-52. Abstract

Professor Dr Peter R Galle, PhD

Bruix J et al. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 2016;150(4):835-53. Abstract

Ikeda M et al. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). ASCO 2018;Abstract 4076.

Kelley K et al. Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy. ASCO 2019;Abstract TPS4157.

Llovet J et al. Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study. ASCO 2019;Abstract TPS4152.

Sangro B et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59(1):81-8. Abstract

Wainberg ZA et al. Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC). ASCO 2017;Abstract 4071.

Yau T et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. ASCO 2019;Abstract 4012.

Ghassan Abou-Alfa, MD

Abou-Alfa GK et al. ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. ESMO 2019;Abstract LBA10_PR.

Bang YJ et al. Clinical outcomes and their correlation with gene expression in patients with advanced gastric cancer treated with pembrolizumab (MK-3475): KEYNOTE-012. ESMO 2017;Abstract LBA-04.

Boscoe AN et al. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: A systematic literature review. J Gastrointest Oncol 2019;10(4):751-65. Abstract

Goyal L et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov 2017;7(3):252-63. Abstract

Javle M et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol 2018;36(3):276-82. Abstract

Lowery MA et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: A phase 1 study. Lancet Gastroenterol Hepatol 2019;4(9):711-20. Abstract

Lowery MA et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: Potential targets for intervention. Clin Cancer Res 2018;24(17):4154-61. Abstract

Popovici-Muller J et al. Discovery of AG-120 (Ivosidenib): A first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett 2018;9(4):300-5. Abstract

Vogel A et al. FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA). ESMO 2019;Abstract LBA40.